Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Drug Approvals in Hepatocellular Carcinoma—Filling the Nonexistent Gap?

Drug Approvals in Hepatocellular Carcinoma—Filling the Nonexistent Gap? This Viewpoint discusses approvals by the US Food and Drug Administration for first- and second-line chemotherapy drugs—plus the combined use of some agents—used to treat hepatocellular carcinoma. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Drug Approvals in Hepatocellular Carcinoma—Filling the Nonexistent Gap?

JAMA Oncology , Volume 7 (2) – Feb 5, 2021

Loading next page...
 
/lp/american-medical-association/drug-approvals-in-hepatocellular-carcinoma-filling-the-nonexistent-gap-vXGTUBhrAj
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.4811
Publisher site
See Article on Publisher Site

Abstract

This Viewpoint discusses approvals by the US Food and Drug Administration for first- and second-line chemotherapy drugs—plus the combined use of some agents—used to treat hepatocellular carcinoma.

Journal

JAMA OncologyAmerican Medical Association

Published: Feb 5, 2021

References